KeasClinical Studies ApS
APSActiveAdvertising protectionCVR 40794492Holger Drachmanns Vej 6, 8000 Aarhus CAll other professional, scientific and technical activities n.e.c.· NACE 7499Est. 2019 · 7 years old1 employees
Loading company…
Overview
KeasClinical Studies ApS is a Danish APS based in Aarhus C, operating in the All other professional, scientific and technical activities n.e.c. sector. Incorporated in 2019, the company has 1 employee and reported a gross profit of -DKK 23.5k in its latest annual filing.
Gross profit 2025
-23.5K DKK
+3470% vs 2024
EBITDA margin (of gross profit)
100.0 %
−3470% vs 2024
Net profit 2025
-14.4K DKK
-2268% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
58.0 %
AverageAround the average of companies in the same industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
2.4×
AverageAround the average of companies in the same industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
-10.6 %
WeakAmong the 30% lowest rated companies in the industry
20212025
EBITDA — year on year
DKK thousandsKey figures
Annual report 2025| Gross profit | -23.5K DKK | +3470% |
| EBITDA | -23.5K DKK | -3470% |
| Net profit | -14.4K DKK | -2268% |
| Total assets | 135K DKK | +11% |
| Equity | 78.3K DKK | -16% |
| Employees | 1 | — |
Company information
Legal name
KeasClinical Studies ApS
CVR number
40794492
Legal form
Anpartsselskab
Founded
18 September 2019 · 7 years
Share capital
DKK 40,000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at drive virksomhed indenfor kliniske studier og anden dermed i forbindelse stående virksomhed.
(no translation available)
Contact
Address
Holger Drachmanns Vej 6, 8000 Aarhus C
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), KeasClinical Studies ApS reported a gross profit of -DKK 23.5k. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of DKK 14.4k.
At the end of 2025, equity financed 58% of the balance sheet, and current assets covered short-term debt 2.4 times.
Financials
Gross profit
DKK thousandsEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross profit | -23 | -1 | -7 | -23 | 151 |
| Staff expenses | -0 | -0 | -0 | -17 | -0 |
| EBITDA | -23 | -1 | -7 | -6 | 151 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -23 | -1 | -7 | -6 | 151 |
| Net financials | 0 | 0 | 0 | -4 | -6 |
| Profit before tax | -23 | -1 | -7 | -10 | 145 |
| Tax | -9 | -0 | -0 | -0 | 32 |
| Net profit | -14 | -1 | -7 | -10 | 113 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 135 | 122 | 101 | 310 | 730 |
| Equity | 78 | 93 | 93 | 303 | 663 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 57 | 29 | 8 | 7 | 67 |
| Total debt | 57 | 29 | 8 | 7 | 67 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
<−999 %
20212025
Equity ratio
58.0 %
AverageAround the average of companies in the same industry
20212025
Return on equity
-18.4 %
Very weakAmong the 20% lowest rated companies in the industry
20212025
Net profit margin (of gross profit)
<−999 %
20212025
Asset turnover (of gross profit)
-0.17×
20212025
Debt / equity
0.72×
AverageAround the average of companies in the same industry
20212025
Sector performance
21 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Very weak
Among the 20% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very weak
Among the 20% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very weak
Among the 20% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Capacity ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioAverage
Around the average of companies in the same industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioAverage
Around the average of companies in the same industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioAverage
Around the average of companies in the same industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityWeak
Among the 40% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 10% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery strong
Among the 20% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioAverage
Around the average of companies in the same industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioAverage
Around the average of companies in the same industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityAverage
Around the average of companies in the same industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityAverage
Around the average of companies in the same industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtVery weak
Among the 20% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery weak
Among the 20% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest rate on debtVery strong
Among the 10% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginWeak
Among the 30% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Interest coverageNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The ability to pay the interest on the company's debt out of its earnings.
Efficiency & development
Equity to contributed capitalWeak
Among the 40% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityWeak
Among the 30% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 20% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LB Management | Management | 2024 |
Former (1)
JB Management | Management | 2019 – 2024 |
Board of directors
Non-executive oversightNo data on file.
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 90–99.99% | 90–99.99% | 2024 | |
| Individual | 5–9.99% | 5–9.99% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Blitz Holding ApS
KeasClinical Studies ApS Board network connections
Board members of KeasClinical Studies ApS also hold positions in 5 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Janus Bliksted Gitz-Johansen | Management | 3 companies |
| Lone Bliksted Gitz-Johansen | Management | 2 companies |
Frequently asked questions
What is the CVR number of KeasClinical Studies ApS?
KeasClinical Studies ApS is registered with CVR / Virk under CVR 40794492.
What is the gross profit of KeasClinical Studies ApS?
KeasClinical Studies ApS reported a gross profit of -DKK 23.5k in 2025.
How many employees does KeasClinical Studies ApS have?
KeasClinical Studies ApS employs 1 people as of the latest annual report.
Where is KeasClinical Studies ApS headquartered?
KeasClinical Studies ApS's registered address is Holger Drachmanns Vej 6.